S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/18 - 9/22
The federal government is headed into a shutdown. What does it mean, who's hit and what's next?
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Auto workers still have room to expand their strike against car makers. But they also face risks
Investing Legend Warns: NVIDIA is a "Delusion" (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Forecast, Price & News

$12.24
+0.02 (+0.16%)
(As of 09/22/2023 ET)
Compare
Today's Range
$12.14
$12.40
50-Day Range
$11.60
$12.49
52-Week Range
$3.00
$13.66
Volume
26,137 shs
Average Volume
34,931 shs
Market Capitalization
$175.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
7.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.64 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.86 out of 5 stars

Medical Sector

958th out of 967 stocks

Pharmaceutical Preparations Industry

443rd out of 444 stocks


MACK stock logo

About Merrimack Pharmaceuticals (NASDAQ:MACK) Stock

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

MACK Price History

MACK Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Merrimack Valley High School
Merrimack Reports Full Year 2022 Financial Results
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MACK Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
10,187,000
Market Cap
$175.28 million
Optionable
Optionable
Beta
1.76

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Gary L. Crocker M.B.A.Mr. Gary L. Crocker M.B.A. (Age 71)
    MBA, Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
    Comp: $76k
  • Dr. Ulrik B. Nielsen Ph.D. (Age 51)
    Co-Founder & Independent Director
    Comp: $72.5k
  • Dr. Anthony J. Sinskey Ph.D. (Age 83)
    Sc.D., Co-Founder and Scientific Advisor
  • Geoffrey Grande C.F.A.
    Sr. Director of Communications
  • Ms. Ellen K. Forest (Age 59)
    Head of HR
  • Dr. Daryl C. Drummond Ph.D. (Age 54)
    Head of Research
  • Mr. Timothy R. Surgenor (Age 63)
    Sec.













MACK Stock - Frequently Asked Questions

How have MACK shares performed in 2023?

Merrimack Pharmaceuticals' stock was trading at $11.46 at the beginning of 2023. Since then, MACK stock has increased by 6.8% and is now trading at $12.24.
View the best growth stocks for 2023 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter.

When did Merrimack Pharmaceuticals' stock split?

Merrimack Pharmaceuticals's stock reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.72%), Dimensional Fund Advisors LP (3.21%), Geode Capital Management LLC (1.70%), Wittenberg Investment Management Inc. (1.43%), State Street Corp (1.22%) and Northern Trust Corp (0.81%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $12.24.

How much money does Merrimack Pharmaceuticals make?

Merrimack Pharmaceuticals (NASDAQ:MACK) has a market capitalization of $175.28 million. The biopharmaceutical company earns $-1,540,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How many employees does Merrimack Pharmaceuticals have?

The company employs 426 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The official website for the company is www.merrimackpharma.com. The biopharmaceutical company can be reached via phone at 617-720-8606, via email at ir@merrimack.com, or via fax at 617-491-1386.

This page (NASDAQ:MACK) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -